Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

Published:2020-06-01 Issue:6 Volume:6 Page:831
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Chen Eric X.¹,Jonker Derek J.²,Loree Jonathan M.³,Kennecke Hagen F.⁴,Berry Scott R.⁵,Couture Felix⁶,Ahmad Chaudhary E.⁷,Goffin John R.⁸,Kavan Petr⁹,Harb Mohammed¹⁰,Colwell Bruce¹¹,Samimi Setareh¹²,Samson Benoit¹³,Abbas Tahir¹⁴,Aucoin Nathalie¹⁵,Aubin Francine¹⁶,Koski Sheryl L.¹⁷,Wei Alice C.¹,Magoski Nadine M.¹⁸,Tu Dongsheng¹⁸,O’Callaghan Chris J.¹⁸

Affiliation:

1. Princess Margaret Cancer Center, Toronto, Canada

2. The Ottawa Hospital, Ottawa, Canada

3. BC Cancer, Vancouver, Canada

4. Virginia Mason Medical Center, Seattle

5. Department of Oncology, Queen’s University, Kingston, Canada

6. CHU de Québec-Université, Laval, Canada

7. Eastern Health, St John’s, Canada

8. Juvravinski Cancer Center, Hamilton, Canada

9. Segal Cancer Center, Montreal, Canada

10. Moncton Hospital, Moncton, Canada

11. Dalhousie University, Halifax, Canada

12. Hôpital Sacré-Coeur de Montréal, Montreal, Canada

13. Sherbrooke University, Sherbrooke, Canada

14. Saskatoon Cancer Center, Saskatoon, Canada

15. Hôpital Cité-de-la-Santé, Laval, Canada

16. Centre de recherche du Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Canada

17. Cross Cancer Center, Edmonton, Canada

18. Canadian Cancer Trials Group, Kingston, Canada

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2765332/jamaoncology_chen_2020_oi_200014.pdf

Reference31 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Bray;CA Cancer J Clin,2018

2. Cancer statistics, 2019.;Siegel;CA Cancer J Clin,2019

3. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial.;Venook;JAMA,2017

4. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.;Stintzing;Lancet Oncol,2016

5. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.;Grothey;Lancet,2013

Cited by 256 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies for the treatment of colorectal cancer;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Optical functional nanomaterials for cancer photoimmunotherapy;Coordination Chemistry Reviews;2024-10

3. Cancer immunotherapy of Wilms tumor: a narrative review;Future Oncology;2024-09-05

4. Integrative analysis of the immunological significances of guanylate binding protein family genes in microsatellite stability colorectal cancer;Heliyon;2024-09

5. A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer;Clinical Colorectal Cancer;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3